661 related articles for article (PubMed ID: 21768546)
1. Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-eluting Stents (ISAR-TEST 5) trial.
Massberg S; Byrne RA; Kastrati A; Schulz S; Pache J; Hausleiter J; Ibrahim T; Fusaro M; Ott I; Schömig A; Laugwitz KL; Mehilli J;
Circulation; 2011 Aug; 124(5):624-32. PubMed ID: 21768546
[TBL] [Abstract][Full Text] [Related]
2. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
[TBL] [Abstract][Full Text] [Related]
3. Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction.
Colleran R; Kufner S; Harada Y; Giacoppo D; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Schneider S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Catheter Cardiovasc Interv; 2017 Feb; 89(3):367-374. PubMed ID: 27377301
[TBL] [Abstract][Full Text] [Related]
4. Five-year clinical outcomes in patients with diabetes mellitus treated with polymer-free sirolimus- and probucol-eluting stents versus second-generation zotarolimus-eluting stents: a subgroup analysis of a randomized controlled trial.
Harada Y; Colleran R; Kufner S; Giacoppo D; Rheude T; Michel J; Cassese S; Ibrahim T; Laugwitz KL; Kastrati A; Byrne RA;
Cardiovasc Diabetol; 2016 Sep; 15(1):124. PubMed ID: 27586678
[TBL] [Abstract][Full Text] [Related]
5. Ten-year clinical outcomes of polymer-free versus durable polymer new-generation drug-eluting stent in patients with coronary artery disease with and without diabetes mellitus : Results of the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol- and Zotarolimus-Eluting Stents (ISAR-TEST 5) trial.
Koch T; Lenz T; Joner M; Xhepa E; Koppara T; Wiebe J; Coughlan JJ; Aytekin A; Ibrahim T; Kessler T; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Kufner S;
Clin Res Cardiol; 2021 Oct; 110(10):1586-1598. PubMed ID: 34156521
[TBL] [Abstract][Full Text] [Related]
6. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial.
Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ
Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051
[TBL] [Abstract][Full Text] [Related]
7. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
[TBL] [Abstract][Full Text] [Related]
8. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.
Kufner S; Ernst M; Cassese S; Joner M; Mayer K; Colleran R; Koppara T; Xhepa E; Koch T; Wiebe J; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
J Am Coll Cardiol; 2020 Jul; 76(2):146-158. PubMed ID: 32646563
[TBL] [Abstract][Full Text] [Related]
9. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
[TBL] [Abstract][Full Text] [Related]
10. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET).
Kimura T; Morimoto T; Natsuaki M; Shiomi H; Igarashi K; Kadota K; Tanabe K; Morino Y; Akasaka T; Takatsu Y; Nishikawa H; Yamamoto Y; Nakagawa Y; Hayashi Y; Iwabuchi M; Umeda H; Kawai K; Okada H; Kimura K; Simonton CA; Kozuma K;
Circulation; 2012 Sep; 126(10):1225-36. PubMed ID: 22824435
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
[TBL] [Abstract][Full Text] [Related]
12. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
13. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
14. Real polymer-free sirolimus- and probucol-eluting versus biodegradable polymer sirolimus-eluting stents for obstructive coronary artery disease: DKPLUS-Wave 1, a multicenter, randomized, prospective trial.
Chen SL; Ye F; Zhang JJ; Zou JJ; Qian XS; Li F; Yang S; Ge Z; Shan SJ; Li XB; Xu T; Kan J; Lin L; Han YL
Cardiovasc Ther; 2013 Aug; 31(4):193-200. PubMed ID: 22954234
[TBL] [Abstract][Full Text] [Related]
15. Differential clinical outcomes after 1 year versus 5 years in a randomised comparison of zotarolimus-eluting and sirolimus-eluting coronary stents (the SORT OUT III study): a multicentre, open-label, randomised superiority trial.
Maeng M; Tilsted HH; Jensen LO; Krusell LR; Kaltoft A; Kelbæk H; Villadsen AB; Ravkilde J; Hansen KN; Christiansen EH; Aarøe J; Jensen JS; Kristensen SD; Bøtker HE; Thuesen L; Madsen M; Thayssen P; Sørensen HT; Lassen JF
Lancet; 2014 Jun; 383(9934):2047-2056. PubMed ID: 24631162
[TBL] [Abstract][Full Text] [Related]
16. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
Serruys PW; Silber S; Garg S; van Geuns RJ; Richardt G; Buszman PE; Kelbaek H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Ronden J; Bressers M; Gobbens P; Negoita M; van Leeuwen F; Windecker S
N Engl J Med; 2010 Jul; 363(2):136-46. PubMed ID: 20554978
[TBL] [Abstract][Full Text] [Related]
17. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.
Byrne RA; Mehilli J; Iijima R; Schulz S; Pache J; Seyfarth M; Schömig A; Kastrati A
Eur Heart J; 2009 Apr; 30(8):923-31. PubMed ID: 19240066
[TBL] [Abstract][Full Text] [Related]
18. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent.
Rozemeijer R; Stein M; Voskuil M; van den Bor R; Frambach P; Pereira B; Koudstaal S; Leenders GE; Timmers L; Rittersma SZ; Kraaijeveld AO; Agostoni P; Roes KC; Doevendans PA; Stella PR;
Circulation; 2019 Jan; 139(1):67-77. PubMed ID: 30586704
[TBL] [Abstract][Full Text] [Related]
19. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
[TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
